Get the Stockscreener App
2.025
1.46%
-0.025
Rani Therapeutics Holdings Inc stock is traded at $2.025, with a volume of 188.10K.
It is down -1.46% in the last 24 hours and down -21.40% over the past month.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.
See More
Previous Close:
$2.05
Open:
$2.04
24h Volume:
188.10K
Relative Volume:
0.12
Market Cap:
$66.44M
Revenue:
$3.04M
Net Income/Loss:
$-33.97M
P/E Ratio:
-1.4674
EPS:
-1.38
Net Cash Flow:
$-52.47M
1W Performance:
-14.04%
1M Performance:
-21.40%
6M Performance:
-60.70%
1Y Performance:
+0.00%
1-Day Range:
$2.01
$2.08
1-Week Range:
$2.00
$2.37
52-Week Range:
$1.90
$8.75
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
Name
Rani Therapeutics Holdings Inc
Sector
Industry
Phone
(408) 457-3700
Address
2051 RINGWOOD AVENUE, SAN JOSE
Compare RANI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| RANI | 2.02 | 66.44M | 3.04M | -33.97M | -52.47M | -1.38 |
| VRTX | 449.28 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.98 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 592.38 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.29 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.94 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jul-27-22 | Initiated | H.C. Wainwright | Buy |
| Jun-13-22 | Initiated | Wedbush | Outperform |
Rani Therapeutics Holdings Inc Stock (RANI) Latest News
RANI: Third Quarter Update - MSN
HC Wainwright Reiterates "Buy" Rating for Rani Therapeutics (NASDAQ:RANI) - MarketBeat
Rani Therapeutics Advances in Biotherapeutics Market - TipRanks
Rani Therapeutics Holdings Inc (RANI) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires New Stake in Rani Therapeutics H - GuruFocus.com
Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update - The Manila Times
Rani Therapeutics Slashes Q3 Loss by 31%, Secures $20M Funding for GLP-1 Development | RANI Stock News - StockTitan
Rani Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Brokerages Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) PT at $11.71 - Defense World
Analysts Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Target Price at $11.71 - MarketBeat
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Sees Significant Growth in Short Interest - MarketBeat
Allied Gaming & Entertainment And 2 Other US Penny Stocks To Watch - Simply Wall St
RANI: New Triagonist Data in Weight Loss - Zacks Small Cap Research
Rani Therapeutics shares hold buy rating on positive preclinical data By Investing.com - Investing.com Australia
Rani Therapeutics stock gets positive outlook from H.C. Wainwright after novel obesity candidate progress - Investing.com Australia
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.75% - MSN
Rani Therapeutics shares hold buy rating on positive preclinical data - Investing.com
Rani Therapeutics (NASDAQ:RANI) Receives "Buy" Rating from HC Wainwright - MarketBeat
Rani Therapeutics reports promising obesity treatment delivery By Investing.com - Investing.com South Africa
Rani therapeutics sees $10 million in stock sales by major investors By Investing.com - Investing.com
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Major Shareholder South Cone Investments Limited Sells 3,829,360 Shares - MarketBeat
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.75% - MSN
Rani Therapeutics reports promising obesity treatment delivery - Investing.com
Rani Therapeutics Announces New Preclinical Pharmacokinetic - GlobeNewswire
Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist - The Manila Times
Rani Therapeutics (RANI) Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist - StreetInsider.com
Rani Therapeutics to sell 3M shares at $3.00 in registered direct offering - MSN
Recent Insider Activity Could Benefit Comcast Corp (CMCSA) - Knox Daily
Market Momentum: Rani Therapeutics Holdings Inc (RANI) Registers a -33.33 Decrease, Closing at 2.12 - The Dwinnex
There is no doubt that Rani Therapeutics Holdings Inc (RANI) ticks all the boxes. - SETE News
An Analysis of Avidity Biosciences Inc (RNA)’s Potential Price Growth - Knox Daily
Form 424B5 Rani Therapeutics Holdin - StreetInsider.com
United States shares lower at close of trade; Dow Jones Industrial Average down 0.75% - MSN
Why Rani Therapeutics Shares Are Down 23% Today - Benzinga
“Peraso Inc. (NASDAQ: PRSO) Revolutionizes Consumer Experiences with Game-Changing mmWave Technology” more stocks inside…. - The Globe and Mail
Rani Therapeutics Holdings Inc [RANI] is -4.22% lower this YTD. Is it still time to buy? - The DBT News
Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 - GlobeNewswire
Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants - StockTitan
3 Penny Stocks to Watch Now, 10/15/24 - TipRanks
Why Ericsson Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Ubiquiti Inc. (NYSE:UI) Shares Sold by Dimensional Fund Advisors LP - Defense World
Rani Therapeutics Holdings Inc (RANI) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
Rani Therapeutics Holdings Inc (NASDAQ:RANI) stock crossing the finish line today - US Post News
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 47%; Here Are 20 Stocks Moving Premarket - Benzinga
Marshall Wace LLP Buys New Shares in Security National Financial Co. (NASDAQ:SNFCA) - Defense World
Marshall Wace LLP Invests $81,000 in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Marshall Wace LLP Buys New Holdings in Hanesbrands Inc. (NYSE:HBI) - Defense World
Investors bid Relief Therapeutics Holding (VTX:RLF) up CHF20m despite increasing losses YoY, taking five-year CAGR to 55% - Yahoo Finance
Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics - Yahoo! Voices
Walgreens: A New Risk Just Emerged for the Stock - Yahoo! Voices
2 Unstoppable Growth Stocks to Buy Right Now for Less Than $500 - Yahoo! Voices
Rani Therapeutics Holdings Inc Stock (RANI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rani Therapeutics Holdings Inc Stock (RANI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Quiroga Cortes Isidoro Alfonso | 10% Owner |
Nov 24 '23 |
Sale |
2.01 |
5,265,165 |
10,582,982 |
8,400 |
| South Cone Investments Limited | 10% Owner |
Nov 24 '23 |
Buy |
2.01 |
5,265,165 |
10,582,982 |
12,131,554 |
| Imran Talat | Chief Executive Officer |
Dec 06 '23 |
Buy |
2.27 |
10,000 |
22,700 |
484,455 |
| Imran Talat | Chief Executive Officer |
Dec 04 '23 |
Buy |
2.57 |
5,000 |
12,850 |
474,455 |
| Imran Talat | Chief Executive Officer |
Nov 29 '23 |
Buy |
2.05 |
20,000 |
41,000 |
469,455 |
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):